CAN-FITE BIOPHARMA LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.6 ILa | -3.70% |
|
-7.14% | 0.00% |
| 05-12 | Transcript : Can-Fite BioPharma Ltd. - Special Call | |
| 05-09 | Can-Fite BioPharma Ltd. Announces FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Compared values
| Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CAN-FITE BIOPHARMA LTD. | Biopharmaceuticals | -3.70% | -7.14% | 0.00% | -23.53% | -92.95% | 10.88M |  | |  |
Technical Rankings Surperformance
- Stock Market
- Equities
- CANF Stock
- Charts Can-Fite BioPharma Ltd.
- Comparison Chart
